89BIO INC. - COMMON STOCK

89bio to Host Key Opinion Leader Webinar on Severe Hypertriglyceridemia (SHTG)

26 апр 2022 08:00:02 Источник Nasdaq GlobeNewswire

89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

24 мар 2022 16:05:01 Источник Nasdaq GlobeNewswire

89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors

24 фев 2022 08:00:02 Источник Nasdaq GlobeNewswire

89bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare Conference

09 фев 2022 08:00:02 Источник Nasdaq GlobeNewswire

89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

24 янв 2022 16:05:00 Источник Nasdaq GlobeNewswire

89bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen Volume 

14 ноя 2021 18:30:00 Источник Nasdaq GlobeNewswire

89bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

11 ноя 2021 16:05:01 Источник Nasdaq GlobeNewswire

89bio Announces Appointment of Kathy LaPorte to its Board of Directors

03 ноя 2021 08:00:01 Источник Nasdaq GlobeNewswire

89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD’s The Liver Meeting 2021

25 окт 2021 16:05:00 Источник Nasdaq GlobeNewswire

89bio to Participate in the Cantor Global Healthcare Conference

21 сен 2021 08:00:01 Источник Nasdaq GlobeNewswire

89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

08 сен 2021 16:15:00 Источник Nasdaq GlobeNewswire

89bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

12 авг 2021 16:05:01 Источник Nasdaq GlobeNewswire

89bio to Participate in Upcoming Investor Conferences

03 авг 2021 16:15:00 Источник Nasdaq GlobeNewswire

89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH

02 авг 2021 08:30:00 Источник Nasdaq GlobeNewswire

89bio to Participate in Upcoming Investor Conferences

16 июн 2021 08:00:00 Источник Nasdaq GlobeNewswire

89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH

10 июн 2021 08:30:00 Источник Nasdaq GlobeNewswire

89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update

12 май 2021 16:05:00 Источник Nasdaq GlobeNewswire

89bio to Present at Upcoming Investor Conferences

05 май 2021 08:00:01 Источник Nasdaq GlobeNewswire

89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH

05 апр 2021 08:00:01 Источник Nasdaq GlobeNewswire

89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

24 мар 2021 16:05:00 Источник Nasdaq GlobeNewswire